[1]陈明艳,徐 伟,杜雯雯,等.我国医保抗肝癌用药分析——基于我国大陆、香港地区、台湾地区及日本的对比[J].卫生经济研究,2019,(04):64-66.
　CHEN Ming-yan,XU Wei,DU Wen-wen,et al.Analysis of Anti-hepatocelluar carcinoma Drugs Used in Medical Insurance in China[J].Journal Press of Health Economics Research,2019,(04):64-66.
点击复制

我国医保抗肝癌用药分析
——基于我国大陆、香港地区、台湾地区及日本的对比
分享到：

卫生经济研究[ISSN:1004-7778/CN:33-1056/F]

卷:
期数:
2019年04期
页码:
64-66
栏目:
药械管理
出版日期:
2019-03-27

文章信息/Info

Title:
Analysis of Anti-hepatocelluar carcinoma Drugs Used in Medical Insurance in China
作者:
陈明艳1; 徐 伟1; 杜雯雯1; 李孟林1; 王煜昊1
1.中国药科大学国际医药商学院 ，江苏 南京 211198
Author(s):
CHEN Ming-yan; XU Wei; DU Wen-wen; LI Meng-lin; WANG Yu-hao
School of International Pharmaceutical Business, China Pharmaceutical University, Nanjing Jiangsu 211198, China
关键词:
肝癌用药; 医保目录; 价格水平
Keywords:
Liver cancer medication;  medical insurance catalogue;  price level
分类号:
F840.684
文献标志码:
A
摘要:
目的：以肝癌用药为例，分析我国大陆、香港地区、台湾地区及日本医保目录的药品收载情况及价格水平，为完善我国大陆医保目录提供参考。方法：对比我国大陆、香港地区、台湾地区及日本医保目录的肝癌用药品种重合及差异情况，并以限定日费用（DDDc）为指标，对其价格水平进行对比。结果：我国大陆、香港地区、台湾地区及日本的医保抗肝癌西药品种数相差不大，但我国大陆多为化疗用药，仅索拉非尼一个靶向药品；我国大陆医保范围内抗肝癌用药日均费用较低，但医保外药品日均费用偏高。结论：我国大陆医保抗肝癌用药品种较多，但靶向药品少，建议动态调整医保目录，及时纳入疗效佳的新药，并通过谈判等方式降低新药价格。
Abstract:
Objective Taking liver cancer medication as an example, this paper analyzed the drug loading situation and price level of and Japan medical insurance catalogues, in order to provide reference for improving mainland China's medical insurance catalogue. Methods The coincidence and difference of liver cancer medications in China and Japan medical insurance catalogues were compared, and the price level of medical insurance for liver cancer was compared with the limited daily cost (DDDc). Results The number of western medicines for liver cancer medical insurance in China and Japan was not much different, but most of the medicines for liver cancer medical insurance in mainland China were chemotherapy drugs, only one target drug, namingly sorafenib. The average cost was lower in mainland China, but the average daily cost of medical insurance was higher. Conclusion Mainland China's liver cancer medical insurance had the most drugs, but there were few targeted drugs. It is recommended to adjust the medical insurance catalogue, timely incorporate new drugs with good curative effect, and reduce the price of new drugs through negotiation and other means.

参考文献/References:

[1] 陈万青,郑荣寿,张思维,等.2013年中国恶性肿瘤发病和死亡分析[J].中国肿瘤,2017,26(1):1-7.
[2] 李潇,方一清,王敏,等.2015年某院肿瘤化疗住院患者疾病构成和费用分析[J].中国病案,2017,18(9):63-66.
[3] 国家统计局. 2017年城镇非私营单位就业人员年平均工资74318元[EB/OL].[2018-05-15]. http://www.stats.gov.cn/tjsj/zxfb/201805/t20180515_1599424.html.
[4] 王雅楠,官海静,刘国恩,等.台湾地区医保药品的采购模式和支付价格[J].中国卫生政策研究,2015,8(12):18-22.
[5] 常峰,崔鹏磊,夏强,等.日本医保药品支付价格调整机制对我国的启示[J].中国医药工业杂志,2015,46(8):915-920.
[6] 国家卫生计生委办公厅.关于印发原发性肝癌诊疗规范（2017年版）的通知[EB/OL]. [2017-06-26]. http://www.nhfpc.gov.cn/yzygj/s7659/201706/80abf02a86c048fcb130e5e298f7aeee.shtml.

相似文献/References:

[1]田梦媛,殷 潇,张欲晓,等.吉非替尼治疗晚期非小细胞肺癌的医保预算影响分析[J].卫生经济研究,2016,(12):25.
[2]钱 然,马爱霞.韩国药品补偿政策及药物经济学应用研究[J].卫生经济研究,2017,(02):46.
[3]陈平钰,李洪超,马爱霞.直接抗病毒药物治疗慢性丙型肝炎患者的预算影响分析[J].卫生经济研究,2019,(01):44.
　CHEN Ping-yu,LI Hong-chao,MA Ai-xia.Budgetary Impact Analysis of Direct Antiviral Drugs in the treatment of Patients with Chronic Hepatitis C[J].Journal Press of Health Economics Research,2019,(04):44.
[4]谭清立,丘丽莹.城市普惠型商业医疗保险比较研究[J].卫生经济研究,2024,41(02):23.
　TAN Qingli,QIU Liying.Comparative Study on Urban Inclusive Commercial Medical Insurance[J].Journal Press of Health Economics Research,2024,41(04):23.

更新日期/Last Update: 2019-03-27